INTRODUCTION
Growth hormone (GH) is a polypeptide chain which is involved in a number of anabolic processes (Wallis, 1985) . A number of reports are available on the primary structure, gene cloning and expression of growth hormone gene (Santome, 1971; Sami, 2006; Sereikeite, 2007; Wallis, 1973 Wallis, , 1985 Wallis, , 2001 Wallis, , 2005 Wallis, , 2006 Verma, 1999; Yato, 1988; Vize, 1987) . GH gene in ruminants comprised of 2.1 KB present at chromosome 19. Bovine GH gene (bGH) has 5 exons and 4 introns. Removal of introns is a critical step in the transcription of the protein, as any event at a potential splicing point could introduce some changes in the nucleotide sequence which could lead to the expression of a GH variant, as it happened in the case of 20k hGH (Denoto, 1981; Rogers and Walls, 1980; Lerner et al., 1980; Seif et al., 1979) . Such potential event has been reported by Woychik et al. (1982) for bovine GH gene at exon 3. Another event has been reported by Hampson and Rottman (1987) in which the inclusion of exon 4 sequence has been reported in mRNA for GH. Researchers are in constant search of the identification of different motifs in GH involved in different functions. GH has its role in a number of anabolic functions like protein synthesis, bone elongation and growth promoting activity. Availability of naturally occurring GH variants has provided some clues identifying the functions of different motifs of GH. Detection of 20k hGH could be considered as an important land mark in this connection.
Revealing of the fact that GH could be used as a tool for increasing farm animals productivity (increase in milk and meat production by the exogenous supply of GH) has made biotechnologist to pay great attention to this molecule (Jones et al., 1994; Mikel, 1993; Seve et al., 1993; Sillence, 2004; Thatcher, 2002) . GH has now been successfully produced as a recombinant protein with proper folding and is being heavily used in the dairy industry. Recombinant GH has been produced as a major protein which is a recombinant DNA-derived GH molecule in the form of insoluble granules. Bioactivity of the recombinant molecule is dependent on the solubility and correct folding of the molecule. For this purpose, the chemistry of the protein has been extensively studied. GH molecule has two disulfide bridges. Correct folding of the molecule is linked to the precise formation of these two bridges. (Langley et al., 1987(a, b) ; Storrs et al., 2001; Baranauskaite, 2005) . Tou et al. (2009) has reported the generation of two novel bGH species generated from a common dehydroalanine intermediate under stressed conditions. Borromeo et al. (2008) has studied the effects of renaturing and storage conditions of mink growth hormone. Introduction of biology computational tools has helped to uncover chemistry, structure and function relationship of GH molecules. De Vos (1992) has reported the crystal structure of the molecule. Previously, structure function studied with reference to molecular modeling has been reported revealing some important features of the molecule (Sami, 2007) . Earlier a ovine growth hormone (oGH) mutant with the deletion of 32-46 amino acid residues was produced, though expressed as a major protein but was unable to refold properly and remained insoluble (Sami, 1991) The present study was aimed to identify the role of domain comprising of 32-46 in bGH/oGH. For this purpose, computational biology tools were used and the molecule was designed and visualized. Such study for bGH/oGH has not been reported so far.
METHODS
Plasmid oGH1 was provided for the preparation of deletion mutant 32-46 by site directed mutagenesis. Production of the mutant has been described earlier (Sami, 1991) , briefly it is given below:
Production of deletion mutant 33-46 of ovine growth hormone by site directed mutagenesis
An oligonucleotide was designed to enable the production of recombinant DNA derived oGH variant equivalent to 20k hGH, involving the deletion of part of loop between helix 1 and helix 2 ( Figure 1 ). The site directed mutagenesis was carried out according to the method as described in Amersham kit for site-directed mutagenesis using DNA sequence coding for OGH1 (Wallis and Wallis, 1988) . The resultant mutant DNA was sequenced by dideoxy sequencing method and was transferred to a pUC 8 plasmid using Eco R1 and Hind III sites. After transformation into JM109 E. coli, the expression of the protein was checked on SDS-PAGE. The expressed protein was isolated and refolded as described by Wallis and Wallis (1990) .
The solubility and refolding of the protein was checked on SDS-PAGE. This part of research was presented in a published PhD thesis of the author submitted to University of Sussex England U K entitled Studies on recombinant DNA derived ovine growth hormone (1991) (Figure 1) . 
Computational methods
Amino acid sequence for bGH accession No. NM_18096 was used (as bGH has more than 99% homology with oGH) and amino acid 33-46 were deleted using computational tool, to make a protein equivalent to 20k bGH. Similarly, hGH accession No. AAA72260) and 20k hGH (after deleting the amino acid residues 32-46) molecules were visualized. The amino acid sequence was submitted to EXPASY server and CPH for molecular model (Arnold et al., 2006; Schwede et al., 2003; Lund et al., 2002) . The model for 20k bGH and wild type bGH were superimposed, to compare the two molecules. Visualized bGH molecule appeared in green while 20k bGH appeared in pink. All the four models were visualized for hydro-phobicity by employing computer program. The hydrophobic regions appeared in blue while hydrophilic regions appeared in red. To analyze the role of hydrogen bonding for wild type and mutant bGH, hydrogen bonds were identified using a display style dialog in the view menu of program. Deleted amino acids from wild type hGH was used to make 20 k hGH, EAYIPQKYSFLQAPQ. Similarly, deleted amino acids from wild type bGH was used to make 20 k bGH, ERTYIPEGERYSIQ.
RESULTS

Production of deletion mutant 33-46 by site directed mutagenesis
Site directed mutagenesis for 33-46 deletion mutant was Sami 713
Figure 3. Molecular model of bGH (green, visible in ribbon structure) super imposed on mutant 20K bGH appeared in pink cylinders using Accelrys DS Visualizer. Previously, the model was prepared on Expassy Server. Difference in the structure of the two proteins is encircled for amino acid residues 33-46 of bGH which are absent in 20k bGH.
carried out using Amersham kit and the method was followed. The resultant DNA was sequenced and the deletion of 42 bases was noticed in the DNA sequence (Figure 1 ). Ovine growth hormone variant, oGH1, with deletion of 33-46 residues was produced by site-directed mutagenesis. The protein which was produced in the form of insoluble granules was solubilized and attempted to refold, using the method employed for refolding of other ovine GH variants (Wallis and Wallis, 1990; Sami et al., 2008) . The results showed that the mutant remained insoluble and did not refold (Lane 2, Figure 2) .
Computational biology
Molecular model of bGH was visualized as ribbon model in green while 20k bGH molecule appeared in pink in cylinders for alpha helices. It was clearly noticed that there was no difference in the global geometry of the molecule. 20 kb GH molecule followed the twisted helical bundle form of the GH molecule arranged in left twisted fashion. The difference observed was the shortening of the first helix and the removal of the coil between helix 1 and 2. The difference is encircled in Figure 3 . The deletion of amino acid residues 33-46 did not alter the three D structure of the molecule. To further investigate the problem, the hydrophobicity of the 20k variant and the wild type bGH and hGH were studied. It was revealed that the change alter the hydrophobicity of the 20k oGH to a greater extent as compared to 20k hGH (Figures 4b  and 4d ). The first helix in case of 20k bGH was completely turned hydrophilic while in case of 20k hGH, the hydrophobicity was reduced as compared to wild type hGH but was not completely altered. When the chemistry of the deleted amino acid residues was compared, it was revealed that for making 20k oGH molecule at three places highly charged amino acid residues E were removed at positions 33, 39 and 41, thus converting hydrophobic core into hydrophilic region. While in case of 20k hGH only one E was removed, justifying the decrease in the hydrophobicity but not introducing the hydrophilicity, as in the case of 20k bGH molecule. Hydrogen bonds play an important role in the chemistry of the molecule. Hydrogen bonds in the region 28-56 of bGH before and after deletion were located. As shown in (Figure 5b ). These results obtained by using bioinformatics tools confirmed previously reported results for recombinant DNA derived oGH molecules having deletion of 33-46 amino acid residues (Figures 3 and 4) . The loop was deleted by site-directed mutagenesis leading to the decreased solubility of the molecule with the protein being produced as insoluble granules. The recombinant protein was insoluble, as the hydrophobicity of the molecule was altered.
DISCUSSION
The Growth hormone variants were studied to identify the structure and function relationship in the molecule. 20k hGH variant has been studied in detail as it has been reported to have shown normal growth promoting activity and little insulin like activity (Lewis et al., 1986) . 20k hGH is a result of mRNA splicing as it plays an important role in the production of GH and GH like proteins. The intervening sequences spliced out of the gene are transcribed to mRNA. Human GH variants such as 17.5k hGH and 20k hGH are the products of such splicing (as reviewed by Wallis, 1985) . Earlier Woychick et al. (1982) has reported that bGH gene also contained a potential alternate RNA splice point at about the same position within the third exon (42 nucleotides from the second intron). The alternate site ends in AG, contains several nucleotides that are consistent with the consensus sequence of RNA splicing and has a significant homology with the U1 RNA (Seif et al., 1979; Moore et al., 1982; Lerner et al., 1980; Roger and Wall, 1980) to determine the effects of deletion of 33-46 amino acid residues in order to relate the structure to the function of the molecule. A mutant protein for oGH1 with deletion of 33-46 amino acid residues was produced by site directed mutagenesis. The sequence analysis of mutant DNA showed that the mutant DNA had a deletion of 42 bases as compared to the original oGH1 DNA. The mutant DNA was transferred to a pUC plasmid and the expression of the protein was checked, as described previously (Wallis and Wallis, 1988; Sami et al., 2008) . The mutant protein was expressed under the control of lac promoter. The mutant expressed as more or less with equal efficiency Sami 715 A.
B. like the original oGH1 protein expressed as major protein (Wallis and Wallis, 1989) , as shown in Figure 2 . The protein was solubilised in 8 M guanidine chloride and was refolded, as described previously. It was observed that the total mutant protein did not solubilised in the buffer at pH 9.5 after treatment for refolding. It showed that the refolded protein has minimum solubility, as compared to the wild type protein. 20k bGH molecule was super-imposed on wild type bGH and it was observed that the deletion did not alter the three dimensional structure of the molecule (Figure 4 ). Both models fit nicely except the part which was deleted from the molecule after the removal, of which four helices remained the initial coordinate. 20k hGH has been studied by workers (Lewis et al., 1978 (Lewis et al., , 1981 and reported that 20k hGH and 22k hGH were not very different from each other in a number of bioassays but may have reduced insulin like activity. Nishikawa et al. (1989) produced 20k GH by recombinant DNA technology and reported that the mutant protein behaved like hGH in weight gain assays, deletion of a part of loop may was compensated for by the flexibility of the loop (Sami, 2007) . It showed that the 20kGH produced as mutant by recombinant DNA technology methods did not alter the folding properties of the molecule. For further investigations, as solubility of the molecules is an important factor, hydrophobicity of the molecule was checked by employing computational biology tools. It was observed that the removal of three E from the mutant altered hydrophobicity of the molecule converted the hydrophobic region into hydrophilic region (Figure 5b) . While in the case of 20 k hGH deletion, the solubility of the molecule was reduced.
It may be noted that the deletion did not alter the bonds formed by Cys 53 indicating that the change did not alter the chemistry of refolding, as the hydrophobic core in GH molecule is not disturbed which provided a driving force to the molecule for refolding (Kauzman, 1959; Sami, 2007; Tsai, 2001) . Perhaps 20k bGH molecule was produced as a result of mRNA alternate splicing but due to its insolubility, it may not be present in the circulation. An example which could be quoted in this regard is of 17.5k hGH, which has been reported to be the result of alternate mRNA splicing in which the mutations in the first and sixth base pair have resulted in misplacing of mRNA and loss of exon 3, so that GH produced from this message lacks amino acid residues 32-71, forming entire connecting loop (Nishikawa et al., 1989; de Vos, 1992; Lecomte et al., 1987; Sami 2007) . Lecomte et al. (1987) has produced the variant by recombinant DNA technology and reported the instability of the molecule. Earlier a C-terminal deletion mutant was produced for ovine growth hormone oGH. Deleted 133-146 (loop between helix 3 and 4) did not alter the biological activity and the refolding of the molecule (Sami et al., 1999) .
Conclusively, the domain comprising of amino acid residues 33-46 in bovine GH and ovine GH is involved in solubilizing the protein molecule. Its removal (as it contains highly charged amino acid residues) could change the global chemistry of the molecule by reducing its solubility.
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